These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 223614)

  • 1. Orally active angiotensin-converting enzyme inhibitor (SO 14,225) as a treatment for essential hypertension.
    Brunner HR; Gavras H; Waeber B; Turini GA; McKinstry DN; Vukovich RA; Gavras I
    Br J Clin Pharmacol; 1979; 7 Suppl 2(Suppl 2):205S-211S. PubMed ID: 223614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of sustained antihypertensive efficacy of chronic captopril therapy: relationships to immediate blood pressure response and control plasma renin activity.
    Waeber B; Gavras I; Brunner HR; Cook CA; Charocopos F; Gavras HP
    Am Heart J; 1982 Mar; 103(3):384-90. PubMed ID: 6278905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of inhibition of converting enzyme by captopril on arterial pressure, renin and aldosterone in essential hypertension].
    Posadas C; Sánchez G; Boyer JL; Delmar M; Serrano PA
    Arch Inst Cardiol Mex; 1982; 52(4):295-300. PubMed ID: 6291470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Participation of the renin system in treatment-resistant hypertension as measured by acute blockade of the angiotensin converting enzyme.
    Weber MA; Drayer JI; Priest RT; Chen TC
    Am J Nephrol; 1982; 2(1):6-11. PubMed ID: 6295161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Captopril in primary hypertension. Effects related to the renin-angiotensin-aldosterone and kallikrein-kinin systems.
    Ohman KP; Karlberg BE; Nilsson OR; Wettre S
    Acta Med Scand Suppl; 1981; 646():98-105. PubMed ID: 7018190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Converting enzyme inhibition with captopril in patients with primary hyperaldosteronism.
    Luderer JR; Demers LM; Harrison TS; Hayes AH
    Clin Pharmacol Ther; 1982 Mar; 31(3):305-11. PubMed ID: 6277545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Converting enzyme inhibition with an orally active compound in hypertensive man.
    Bravo EL; Tarazi RC
    Hypertension; 1979; 1(1):39-46. PubMed ID: 232490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of captopril (SQ 14225) on blood pressure, plasma renin activity and angiotensin I converting enzyme activity.
    Larochelle P; Genest J; Kuchel O; Boucher R; Gutkowska Y; McKinstry D
    Can Med Assoc J; 1979 Aug; 121(3):309-16. PubMed ID: 223756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A new principle in long-term treatment of essential hypertension: angiotensin-converting enzyme inhibition (author's transl)].
    Overlack A; Stumpe KO; Heck I; Krück F
    Dtsch Med Wochenschr; 1980 Apr; 105(15):505-9. PubMed ID: 6244920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A discrepancy between the effects of a single oral dose of captopril on blood pressure, plasma renin activity, and serum angiotensin-converting enzyme levels.
    Lechi A; Covi G; Capuzzo MG; Lechi C; Minuz P; Delva P; Scuro LA
    Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):569-74. PubMed ID: 6317579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition.
    Atkinson AB; Morton JJ; Brown JJ; Davies DL; Fraser R; Kelly P; Leckie B; Lever AF; Robertson JI
    Br Heart J; 1980 Sep; 44(3):290-6. PubMed ID: 7000102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects.
    Lewis RA; Baker KM; Ayers CR; Weaver BA; Lehman MR
    J Cardiovasc Pharmacol; 1985; 7 Suppl 1():S12-5. PubMed ID: 2580164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of moderate to severe hypertensive patients with an orally active converting-enzyme inhibitor.
    Prins EJ; Donker AJ; Hoorntje SJ; Leenen FH; van der Hem GK
    Proc Eur Dial Transplant Assoc; 1979; 16():603-9. PubMed ID: 232914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of converting enzyme inhibition on blood pressure, plasma renin activity (PRA) and plasma aldosterone in hypertensive diabetics compared to patients with essential hypertension.
    Sullivan PA; Kelleher M; Twomey M; Dineen M
    J Hypertens; 1985 Aug; 3(4):359-63. PubMed ID: 2995484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose captopril: its use in mild to moderate hypertension unresponsive to diuretic treatment.
    Vlasses PH; Rotmensch HH; Swanson BN; Mojaverian P; Ferguson RK
    Arch Intern Med; 1982 Jun; 142(6):1098-101. PubMed ID: 6284081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the angiotensin converting enzyme inhibitor, captopril, in essential hypertension.
    Campbell BC; Shepherd AN; Reid JL
    Br J Clin Pharmacol; 1982 Feb; 13(2):213-7. PubMed ID: 6277356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment of hypertension in man by an orally active angiotensin-converting enzyme inhibitor.
    Brunner HR; Gavras H; Turini GA; Waeber B; Cappuis P; McKinstry DN
    Clin Sci Mol Med Suppl; 1978 Dec; 4():293s-295s. PubMed ID: 215374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme.
    MacGregor GA; Markandu ND; Roulston JE; Jones JC
    Br Med J; 1979 Nov; 2(6198):1106-9. PubMed ID: 229941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical experience with an oral angiotensin I-converting enzyme inhibitor in hypertensive patients: effects on blood pressure and the renin-aldosterone system by a single dose (author's transl)].
    Mizuno K; Shigetomi S; Haruyama K; Matsui J; Gotho M; Fukuchi S
    Nihon Jinzo Gakkai Shi; 1980 Jan; 22(1):1-11. PubMed ID: 6247526
    [No Abstract]   [Full Text] [Related]  

  • 20. Fluctuations in the plasma angiotensin I converting enzyme activity during long-term treatment with captopril.
    Staessen J; Fagard R; Lijnen P; Verschueren LJ; Amery A
    Acta Cardiol; 1982; 37(1):1-9. PubMed ID: 6282024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.